The anti-malaria agent artesunate exhibits cytotoxic effects in primary effusion lymphoma

Summary Primary effusion lymphoma (PEL), caused by Kaposi’s sarcoma-associated herpesvirus (KSHV), presents as a lymphomatous effusion in body cavities and has a poor prognosis. The anti-malaria drug, artesunate, possesses anti-neoplastic potential. Therefore, we aimed to investigate its effect on K...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2021-02, Vol.39 (1), p.111-121
Hauptverfasser:	Ishikawa, Chie, Mori, Naoki
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - pharmacology Apoptosis - drug effects Artesunate Artesunate - pharmacology Bcl-x protein c-Myc protein Caspase Caspases - drug effects Cell Line, Tumor Cell Proliferation - drug effects Cell Survival - drug effects Cyclin D1 Cyclin-dependent kinase 2 Cytotoxicity Deoxyribonucleic acid DNA DNA damage DNA Damage - drug effects Effusion Female G1 phase Herpesvirus 8, Human - drug effects Herpesvirus 8, Human - genetics Humans I-kappa B Kinase - drug effects JunB protein Kaposi's sarcoma Kaposis sarcoma Kinases Leukocytes (mononuclear) Lymphoma Lymphoma, Primary Effusion - pathology Malaria Medicine Medicine & Public Health Mice Mice, SCID Myc protein NF-KappaB Inhibitor alpha - drug effects NF-κB protein Oncology Peripheral blood mononuclear cells Pharmacology/Toxicology Phosphorylation Preclinical Studies Primary effusion lymphoma Reactive oxygen species Reactive Oxygen Species - metabolism Sarcoma Signal Transduction - drug effects Survivin Toxicity Transcription factors Vector-borne diseases XIAP protein
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!